NEW YORK, April 29, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it will participate in the upcoming ThinkEquity Conference on May 2, 2019 in New York City. [...]
NEW YORK, April 11, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it will participate in the upcoming 3rd Annual Clinical Trials Summit, taking place on April [...]
NEW YORK, April 4, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that its U.S. patent for the technology "Methods and Compositions for Oral Administration of Exenatide" has been [...]
NEW YORK, April 3, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming H.C. Wainwright Global Life Sciences Conference, taking place [...]
NEW YORK, March 28, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that its U.S. patent for the technology "Protease Inhibitor-Containing Compositions, Compositions Comprising Same, and Methods for [...]
NEW YORK, March 26, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that its Chinese partner, Hefei Tianhui Incubator of Technologies Co., Ltd. ("HTIT"), has reached the significant regulatory milestone of [...]
NEW YORK, Feb. 6, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming BIO CEO & Investor Conference, taking place [...]
JERUSALEM, Jan. 22, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has begun recruitment for its Phase 1 pharmacokinetic (PK) study for ORMD-0901, its oral GLP-1 [...]
JERUSALEM, Jan. 15, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com) Dear Shareholders, We opened the year 2019 with the announcement of our receipt of a $3 million milestone payment from our partners HTIT, thereby increasing our total payments from HTIT received [...]
Totaling $33 M in payments from HTIT received to date JERUSALEM, Jan. 9, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has received a milestone payment of [...]